Rapid Molecular Assay Detects Pneumonia Causative Agents
By LabMedica International staff writers Posted on 16 May 2012 |
A rapid real-time polymerase chain reaction assay (qPCR) has been developed for detecting two microrganisms that cause pneumonia directly from respiratory specimens.
The assay provides over five times faster results compared to existing methods while maintaining equivalent detection rates for specimens containing limited target organisms such as Mycoplasma pneumoniae and Chlamydophila (Chlamydia) pneumoniae.
Scientists the Respiratory Diseases Branch, of the US Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA) developed and evaluated individual singleplex assays for each pathogen and a multiplex assay for simultaneous detection of M. pneumoniae, C. pneumoniae, and human DNA. Nasopharyngeal and/or oropharyngeal clinical specimens were collected by the Centers for Disease Control and Prevention during domestic outbreaks between 2007 and 2009.
Primers and probes previously designed and optimized for specific detection of the ATPase Mp3 for M. pneumoniae, the arginine repressor (argR) of C. pneumoniae, and human nucleic acid (RNase P) were used in the study. For singleplex reactions, the reaction mix contained PerfeCTa qPCR FastMix and for multiplex reactions the PerfeCTa Multiplex qPCR SuperMix was used, and both are products of Quanta Biosciences, (Gaithersburg, MD, USA). Total nucleic acid (TNA) was extracted from universal transport media (UTM) using a Nucleic Acid Isolation Kit I on the MagNA Pure Compact instrument (Roche Applied Science, Indianapolis, IN, USA).
The scientists found a greater than 90% concordance using the rapid singleplex or multiplex assay. They then assessed the performance of the rapid real-time PCR assay using UTM directly from clinical specimens without nucleic acid extraction. Of the specimens identified as positive by standard real-time PCR, 90% and 59% of UTM samples were positive for M. pneumoniae and C. pneumoniae, respectively, using singleplex assays. These percentages dropped to 69% for M. pneumoniae and 52% for C. pneumoniae when tested with the rapid multiplex assay.
The authors concluded that although some loss of sensitivity was observed when performing rapid real-time PCR without a separate extraction step, this method may still be a valuable tool for identification of M. pneumoniae and C. pneumoniae infections in the primary care setting that would otherwise go unnoticed or misdiagnosed. Point-of-care testing would likely improve patient treatment, reduce inappropriate antibiotic use, and have utility for rapid pathogen detection in situations where prompt results are critical. The study was published on April 25 2012 in the journal Diagnostic Microbiology and Infectious Disease.
Related Links:
US Centers for Disease Control and Prevention
Quanta Biosciences
Roche Applied Science
The assay provides over five times faster results compared to existing methods while maintaining equivalent detection rates for specimens containing limited target organisms such as Mycoplasma pneumoniae and Chlamydophila (Chlamydia) pneumoniae.
Scientists the Respiratory Diseases Branch, of the US Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA) developed and evaluated individual singleplex assays for each pathogen and a multiplex assay for simultaneous detection of M. pneumoniae, C. pneumoniae, and human DNA. Nasopharyngeal and/or oropharyngeal clinical specimens were collected by the Centers for Disease Control and Prevention during domestic outbreaks between 2007 and 2009.
Primers and probes previously designed and optimized for specific detection of the ATPase Mp3 for M. pneumoniae, the arginine repressor (argR) of C. pneumoniae, and human nucleic acid (RNase P) were used in the study. For singleplex reactions, the reaction mix contained PerfeCTa qPCR FastMix and for multiplex reactions the PerfeCTa Multiplex qPCR SuperMix was used, and both are products of Quanta Biosciences, (Gaithersburg, MD, USA). Total nucleic acid (TNA) was extracted from universal transport media (UTM) using a Nucleic Acid Isolation Kit I on the MagNA Pure Compact instrument (Roche Applied Science, Indianapolis, IN, USA).
The scientists found a greater than 90% concordance using the rapid singleplex or multiplex assay. They then assessed the performance of the rapid real-time PCR assay using UTM directly from clinical specimens without nucleic acid extraction. Of the specimens identified as positive by standard real-time PCR, 90% and 59% of UTM samples were positive for M. pneumoniae and C. pneumoniae, respectively, using singleplex assays. These percentages dropped to 69% for M. pneumoniae and 52% for C. pneumoniae when tested with the rapid multiplex assay.
The authors concluded that although some loss of sensitivity was observed when performing rapid real-time PCR without a separate extraction step, this method may still be a valuable tool for identification of M. pneumoniae and C. pneumoniae infections in the primary care setting that would otherwise go unnoticed or misdiagnosed. Point-of-care testing would likely improve patient treatment, reduce inappropriate antibiotic use, and have utility for rapid pathogen detection in situations where prompt results are critical. The study was published on April 25 2012 in the journal Diagnostic Microbiology and Infectious Disease.
Related Links:
US Centers for Disease Control and Prevention
Quanta Biosciences
Roche Applied Science
Latest Microbiology News
- New Blood Test Detects Up to Five Infectious Diseases at POC
- Molecular Stool Test Shows Potential for Diagnosing TB in Adults with HIV
- New Test Diagnoses Bacterial Meningitis Quickly and Accurately
- Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
- New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
- Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
- Innovative ID/AST System to Help Diagnose Infectious Diseases and Combat AMR
- Gastrointestinal Panel Delivers Rapid Detection of Five Common Bacterial Pathogens for Outpatient Use
- Rapid PCR Testing in ICU Improves Antibiotic Stewardship
- Unique Genetic Signature Predicts Drug Resistance in Bacteria
- Unique Barcoding System Tracks Pneumonia-Causing Bacteria as They Infect Blood Stream
- Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application
- Rapid Diagnostic System to Detect Neonatal Sepsis Within Hours
- Novel Test to Diagnose Bacterial Pneumonia Directly from Whole Blood
- Interferon-γ Release Assay Effective in Patients with COPD Complicated with Pulmonary Tuberculosis
- New Point of Care Tests to Help Reduce Overuse of Antibiotics
Channels
Clinical Chemistry
view channel
AI-Powered Blood Test Accurately Detects Ovarian Cancer
Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more
Automated Decentralized cfDNA NGS Assay Identifies Alterations in Advanced Solid Tumors
Current circulating cell-free DNA (cfDNA) assays are typically centralized, requiring specialized handling and transportation of samples. Introducing a flexible, decentralized sequencing system at the... Read moreMass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication
Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more
First Comprehensive Syphilis Test to Definitively Diagnose Active Infection In 10 Minutes
In the United States, syphilis cases have surged by nearly 80% from 2018 to 2023, with 209,253 cases recorded in the most recent year of data. Syphilis, which can be transmitted sexually or from mother... Read moreMolecular Diagnostics
view channel
Microbial Cell-Free DNA Test Accurately Identifies Pathogens Causing Pneumonia and Other Lung Infections
Bronchoalveolar lavage (BAL) is a commonly used procedure for diagnosing lung infections, especially in immunocompromised patients. However, standard tests often fail to pinpoint the exact pathogen, leading... Read more
Non-Biopsy Approach to Transform Adult Celiac Disease Diagnoses
In the United States, the diagnosis of celiac disease in adults typically relies on a combination of serologic testing and a confirmatory small bowel biopsy during upper endoscopy. In contrast, European... Read moreHematology
view channel
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read more
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read morePathology
view channel
Groundbreaking Chest Pain Triage Algorithm to Transform Cardiac Care
Cardiovascular disease is responsible for a third of all deaths worldwide, and chest pain is the second most common reason for emergency department (ED) visits. With EDs often being some of the busiest... Read more
AI-Based Liquid Biopsy Approach to Revolutionize Brain Cancer Detection
Detecting brain cancers remains extremely challenging, with many patients only receiving a diagnosis at later stages after symptoms like headaches, seizures, or cognitive issues appear. Late-stage diagnoses... Read moreTechnology
view channel
Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer
Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more